PODD Investors Have Rights - If You Lost Money Investing in Insulet Corporation Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD ) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and internationally.

What is the class period? February 21, 2025 – May 26, 2026

What are the allegations? Shareholders allege that Insulet Corporation misled investors regarding the viability of its products. According to the complaint, during the class period, defendants failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. Plaintiff alleges that on March 12, 2026, Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring" (the "March 2026 MDC"). On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026. Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction" (the "May 2026 MDC"), this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per s...